CHOSA Oncology AB approved for re-listing at Spotlight’s ordinary list
CHOSA Oncology AB (the ”Company” or ”CHOSA Oncology”) have received approval for re-listing on Spotlight’s ordinary list. Spotlight decided by December 5[th] 2022 that the Company was a subject to a new listing process. The reason for the new listing process was to ensure that the Company fulfills all the listing requirements after the Company entered into an agreement to acquire all shares in Chosa ApS (”Chosa ApS”) through reversed merger. The Company has received approval for re-listing and will be transferred to Spotlights ordinary list from today, May 3[ rd] 2023. The share has been